Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Zhuang Y, Calderon C, Marciniak SJ Jr, Bouman-Thio E, Szapary P, Yang TY, Schantz A, Davis HM, Zhou H, Xu Z. Zhuang Y, et al. Among authors: calderon c. Eur J Clin Pharmacol. 2016 Nov;72(11):1303-1310. doi: 10.1007/s00228-016-2110-5. Epub 2016 Aug 11. Eur J Clin Pharmacol. 2016. PMID: 27515978 Clinical Trial.
Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol.
Kuhn A, Wozniacka A, Szepietowski JC, Gläser R, Lehmann P, Haust M, Sysa-Jedrzejowska A, Reich A, Oke V, Hügel R, Calderon C, de Vries DE, Nyberg F. Kuhn A, et al. Among authors: calderon c. J Invest Dermatol. 2011 Aug;131(8):1622-30. doi: 10.1038/jid.2011.101. Epub 2011 May 19. J Invest Dermatol. 2011. PMID: 21593767 Free article. Clinical Trial.
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG. Sofen H, et al. Among authors: calderon c. J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025. J Allergy Clin Immunol. 2014. PMID: 24679469 Free article. Clinical Trial.
Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study.
Boyle DL, DePrimo SE, Calderon C, Chen D, Dunford PJ, Barchuk W, Firestein GS, Thurmond RL. Boyle DL, et al. Among authors: calderon c. Inflamm Res. 2019 Apr;68(4):261-274. doi: 10.1007/s00011-019-01218-y. Epub 2019 Feb 9. Inflamm Res. 2019. PMID: 30739130 Clinical Trial.
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, van der Heijde D. Deodhar A, et al. Among authors: calderon c. Arthritis Rheumatol. 2019 Feb;71(2):258-270. doi: 10.1002/art.40728. Epub 2018 Dec 29. Arthritis Rheumatol. 2019. PMID: 30225992 Clinical Trial.
454 results